Amylin’s Byetta LAR Lowers Glucose, Weight
This article was originally published in The Pink Sheet Daily
Executive Summary
Diabetes market is big enough for liraglutide and other drugs, Amylin CEO tells “The Pink Sheet” DAILY.
You may also be interested in...
Amylin Submits Once-Weekly Byetta After Shedding 200 Sales Reps
Label with expanded language about thyroid cancer risk is expected.
Amylin Submits Once-Weekly Byetta After Shedding 200 Sales Reps
Label with expanded language about thyroid cancer risk is expected.
Novo Nordisk’s Liraglutide Set For March 2009 PDUFA
Phase II study of once-weekly GLP-1 analog is under way, with results due next year.